A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been ...

In advanced stages, dry AMD progresses into geographic atrophy (GA), characterized by atrophy of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris, responsible for a ...

Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator ...

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.